Irsko - angličtina - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - diazepam - emulsion for injection - 5 milligram(s)/millilitre - benzodiazepine derivatives; diazepam

Izrael - angličtina - Ministry of Health

concept for pharmacy ltd - indocyanine green as monosodium salt - powder for solution for injection - indocyanine green as monosodium salt 25 mg/vial - in cardiac, ciculatory and micro-circulatory diagnostics: measurement of circulation times, measurement of cardiac output and stroke volume, measurement of end-systolic ventricular volume, measurement of intrathoracic blood volume, measurement of circulationg blood volume,measurement of partial volumes, measurement of organ perfusion-measurement of intra-and extracardiac shunts, measurement of intracardiac valvular insufficiency, measurement of peripheral perfusion (e.g. perfusion of extremities, eyes). in liver function diagnostics: measurement of excretory function of the liver, determination of partial functions of the liver.

Izrael - angličtina - Ministry of Health

concept for pharmacy ltd - indocyanine green as monosodium salt - powder for solution for injection - indocyanine green as monosodium salt 25 mg/vial - in cardiac, ciculatory and micro-circulatory diagnostics: measurement of circulation times, measurement of cardiac output and stroke volume, measurement of end-systolic ventricular volume, measurement of intrathoracic blood volume, measurement of circulationg blood volume,measurement of partial volumes, measurement of organ perfusion-measurement of intra-and extracardiac shunts, measurement of intracardiac valvular insufficiency, measurement of peripheral perfusion (e.g. perfusion of extremities, eyes). in liver function diagnostics: measurement of excretory function of the liver, determination of partial functions of the liver.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rifampicin 600mg - injection with diluent - 600 mg - active: rifampicin 600mg excipient: sodium formaldehydesulfoxylate sodium hydroxide water for injection polysorbate 80 water for injection - tuberculosis rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. rifampicin should be used in conjunction with at least one other antituberculosis medicine. leprosy rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. rifampicin should be used in conjunction with at least one other anti-leprosy drug. methicillin-resistant staphylococcal infections (mrsa) rifampicin can be used as an alternative to vancomycin in the treatment of mrsa. in such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. serious staphylococcal infections rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. in such circumstances an appropriate companion antibiotic should be employed. brucellosis rifampicin may be used for the treatment of brucellosis. in such circumstances doxycycline should also be used. meningococcal carriers rifampicin is indicated for the treatment of asymptomatic carriers of n. meningitidis to eliminate meningococci from the nasopharynx. (rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). haemophilus influenzae rifampicin is indicated for the treatment of asymptomatic carriers of h influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. other infections infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, n gonorrhoeae, proteus sp., h. influenzae, e. coli and legionella sp. to prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - diazepam - emulsion for injection - 5 mg/ml - benzodiazepine derivatives

Kanada - angličtina - Health Canada

mda inc. - linezolid - solution - 2mg - linezolid 2mg - oxazolidinones

Spojené státy - angličtina - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr) - rifampin 600 mg - in the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin for injection, usp and they should be repeated throughout therapy to monitor the response to treatment.  since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. if test results show resistance to rifampin for injection, usp and the patient is not responding to therapy, the drug regimen should be modified. rifampin for injection, usp is indicated in the treatment of all forms of tuberculosis. a three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short-course therapy which is usually continued for 2 months. the advisory council f

Spojené státy - angličtina - NLM (National Library of Medicine)

mylan institutional llc - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr) - rifampin 600 mg in 10 ml - in the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. if test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. rifampin is indicated in the treatment of all forms of tuberculosis. a three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short-course therapy which is usually continued for 2 months. the advisory council for the elimination of tuberculosis, the american thoracic society, and centers for disease control and prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (inh), rifampin, and pyrazinamide for initial treatment of tuberculosis unless the likelihood of inh resistance is very low. the need for a fourth drug should be reassessed when the results of susceptibility testing are known. if community rates of inh resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. following the initial phase, treatment should be continued with rifampin and isoniazid for at least 4 months. treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is hiv positive. rifampin for injection, usp is indicated for the initial treatment and retreatment of tuberculosis when the drug cannot be taken by mouth. rifampin is indicated for the treatment of asymptomatic carriers of neisseria meningitidis to eliminate meningococci from the nasopharynx. rifampin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms. (see warnings .) rifampin should not be used indiscriminately, and, therefore, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed for establishment of the carrier state and the correct treatment. so that the usefulness of rifampin in the treatment of asymptomatic meningococcal carriers is preserved, the drug should be used only when the risk of meningococcal disease is high. to reduce the development of drug-resistant bacteria and maintain the effectiveness of rifampin and other antibacterial drugs, rifampin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. rifampin is contraindicated in patients with a history of hypersensitivity to rifampin or any of the components, or to any of the rifamycins. (see warnings .) rifampin is contraindicated in patients who are also receiving ritonavir-boosted saquinavir due to an increased risk of severe hepatocellular toxicity. (see precautions, drug interactions .) rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs, which may result in loss of antiviral efficacy and/or development of viral resistance. rifampin is contraindicated in patients receiving praziquantel since therapeutically effective blood levels of praziquantel may not be achieved. in patients receiving rifampin who need immediate treatment with praziquantel alternative agents should be considered. however, if treatment with praziquantel is necessary, rifampin should be discontinued 4 weeks before administration of praziquantel. treatment with rifampin can then be restarted one day after completion of praziquantel treatment. rifampin is contraindicated in patients receiving lurasidone. concomitant use of lurasidone with strong cyp3a4 inducers (e.g., rifampin) decreased the exposure of lurasidone compared to the use of lurasidone alone. (see precautions, drug interactions ).

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rifamycin sodium - capsule - 150mg, 300mg - active: rifamycin sodium

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

laboratoires bouchara-recordati 68 rue marjolin 92300 levallois perret - rifamycin (rifamycin sodium) - drops ear - 26mg (20000iu)/ml